- Conditions
- Cystic Fibrosis
- Interventions
- AZLI 75 mg three times a day (TID), Placebo three times a day (TID)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 314
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hepatitis B, HIV Infection
- Interventions
- Adefovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pseudomonas Infection
- Interventions
- Ciprofloxacin (Cipro, BAYQ3939)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Critical Illness, COVID-19, PICS, Cognitive Impairment, Mental Health Impairment, Weakness, Muscle, Dysbiosis
- Interventions
- Fermented Food Diet
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
- Interventions
- AZLI 75 mg three times daily (TID), Placebo three times daily (TID)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 26 more
- Conditions
- Cystic Fibrosis
- Interventions
- Exhaled Breath Condensate
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Cervical Carcinoma, Locally Advanced Endometrial Carcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Locally Advanced Unresectable Cervical Carcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Renal Cell Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Skin Squamous Cell Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Cervical Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma, Breast Adenocarcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Interventions
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab, Sargramostim, Biospecimen Collection, Biopsy, Computed Tomography, Magnetic Resonance Imaging
- Drug · Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Cystic Fibrosis
- Interventions
- Vancomycin hydrochloride inhalation powder, Placebo inhalation powder
- Drug
- Lead sponsor
- Savara Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more
- Conditions
- Colic, Gastrointestinal Tract Infections
- Interventions
- L. reuteri, Sunflower Oil
- Biological
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sarcopenia, Dietary Exposure, Microbial Colonization
- Interventions
- Low-soluble fiber diet, High-soluble fiber diet
- Other
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Solid Tumors
- Interventions
- Venetoclax, Rovalpituzumab Tesirine, ABBV-181
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 5
- States / cities
- La Jolla, California • Chicago, Illinois • Huntersville, North Carolina + 2 more
- Conditions
- HIV Infections
- Interventions
- raltegravir, Study NNRTI, Study PI
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- Advanced Malignancies, Metastatic Cancer
- Interventions
- INCAGN01876, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more
- Conditions
- Cystic Fibrosis, Lung Disease, Pseudomonas Infections
- Interventions
- CF newborn screening
- Procedure
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 1 Month to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin • Milwaukee, Wisconsin
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging
- Drug · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cancer, Cardiac Disease, Pulmonary Disease, Neuro-Degenerative Disease, Renal Disease, Stroke, Sepsis, Hepatic Disease
- Interventions
- Active Intervention, Usual Care
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Alexander City, Alabama • Meridian, Mississippi • Picayune, Mississippi + 1 more
- Conditions
- Breast Cancer, Breast Cancer Female, Genetic Predisposition to Disease
- Interventions
- Cephalexin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Prematurity; Extreme, Feeding Disorder Neonatal, Breast Milk Expression, Growth Failure, Microbial Colonization
- Interventions
- Protein-enriched human milk diet, Usual human milk diet
- Procedure
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Day to 4 Days
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cystic Fibrosis
- Interventions
- KB001-A, Placebo Comparator
- Biological · Drug
- Lead sponsor
- Humanigen, Inc.
- Industry
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 58
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
- Conditions
- Heart Failure, Gut Microbiome, Nutritional Deficiency
- Interventions
- Ensure Surgery Immunonutrition shake
- Dietary Supplement
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Appendicitis, Evidence of Cholecystectomy, Gallstones, Pregnancy, Ectopic, Aortic Aneurysm, Kidney Stones, Intrauterine Pregnancy, Diverticulitis, Abdominal Injuries, Tumors, Pancreatitis, Digestive System Diseases, Gastrointestinal Diseases, Intraabdominal Infections, Intestinal Diseases, Pregnancy, Vascular Disease, Uterine Fibroids, Ovarian Cysts, Uterine Abnominalies, Bladder Abnominalies, Testicular Abnominalies, Polyps
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 174 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Neoplasms
- Interventions
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
- Drug
- Lead sponsor
- Vincerx Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 13
- States / cities
- Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
- Conditions
- Surgical Wound Infection, Cystitis, Bacteremia, Pneumonia, Enterocolitis, Pseudomembranous
- Interventions
- Synbiotic 2000
- Drug
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York